Novel routes to bipolar disorder drug discovery

Bibliography

• Frye MA. Clinical practice. Bipolar disorder–a focus on depression. N Engl J Med Jan 2011;364(1):51-9
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Akiskal HS, Angst J, Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64(5):543-52
   PubMed Web of Science ®Google Scholar
• Hoertel N, Le Strat Y, Angst J, Dubertret C. Subthreshold bipolar disorder in a U.S. national representative sample: prevalence, correlates and perspectives for psychiatric nosography. J Affect Disord 2013;146(3):338-47
   PubMed Web of Science ®Google Scholar
• Hoertel N, Le Strat Y, Limosin F, Prevalence of subthreshold hypomania and impact on internal validity of RCTs for major depressive disorder: results from a national epidemiological sample. PLoS One 2013;8(2):e55448
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius V, Warnock A, Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007;9(4):394-412
   PubMed Web of Science ®Google Scholar
• Beaulieu JM, Zhang X, Rodriguiz RM, Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 2008;105(4):1333-8
   PubMed Web of Science ®Google Scholar
• Gould TD, Quiroz JA, Singh J, Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 2004;9(8):734-55
   PubMed Web of Science ®Google Scholar
• McClung CA. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007;114(2):222-32
   PubMed Web of Science ®Google Scholar
• Roybal K, Theobold D, Graham A, Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci USA 2007;104(15):6406-11
   PubMed Web of Science ®Google Scholar
• Soreca I, Fagiolini A, Frank E, Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. J Psychiatr Res 2008;42(11):956-61
   PubMed Web of Science ®Google Scholar
• Bijur GN, Jope RS. Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport 2003;14(18):2415-19
   PubMed Web of Science ®Google Scholar
• Bertolino A, Frye M, Callicott JH, Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biol Psychiatry 2003;53(10):906-13
   PubMed Web of Science ®Google Scholar
• Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010;67(4):360-8
   PubMed Web of Science ®Google Scholar
• Linseman DA, Butts BD, Precht TA, Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 2004;24(44):9993-10002
   PubMed Web of Science ®Google Scholar
• Bachmann RF, Schloesser RJ, Gould TD, Manji HK. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 2005;32(2):173-202
   PubMed Web of Science ®Google Scholar
• Alsaif M, Haenisch F, Guest PC, Challenges in drug target discovery in bipolar disorder. Expert Opin Ther Targets 2013;17(5):565-77
   PubMed Web of Science ®Google Scholar
• Gurvich N, Klein PS. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther 2002;96(1):45-66
   PubMed Web of Science ®Google Scholar
• Gould TD, Zarate CA, Manji HK. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 2004;65(1):10-21
   PubMed Web of Science ®Google Scholar
• Rayasam GV, Tulasi VK, Sodhi R, Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009;156(6):885-98
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Salvadore G, DiazGranados N, New therapeutic targets for mood disorders. ScientificWorldJournal 2010;10:713-26
   PubMed Web of Science ®Google Scholar
• Schloesser RJ, Huang J, Klein PS, Manji HK. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008;33(1):110-33
   PubMed Web of Science ®Google Scholar
• Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004;7(4):387-90
   PubMed Web of Science ®Google Scholar
• Manji HK, Lenox RH. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999;46(10):1328-51
   Google Scholar
• Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008;33(9):2080-92
   PubMed Web of Science ®Google Scholar
• Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005;10(10):900-19
   PubMed Web of Science ®Google Scholar
• Lan MJ, McLoughlin GA, Griffin JL, Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry 2009;14(3):269-79
   PubMed Web of Science ®Google Scholar
• Kim H, McGrath BM, Silverstone PH. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders–focus on magnetic resonance spectroscopy (MRS) studies. Hum Psychopharmacol 2005;20(5):309-26
   PubMed Web of Science ®Google Scholar
• Einat H, Yuan P, Szabo ST, Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007;55(3-4):123-31
   PubMed Web of Science ®Google Scholar
• Baum AE, Akula N, Cabanero M, A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008;13(2):197-207
   PubMed Web of Science ®Google Scholar
• Bebchuk JM, Arfken CL, Dolan-Manji S, A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000;57(1):95-7
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ, Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007;9(6):561-70
   PubMed Web of Science ®Google Scholar
• Yildiz A, Guleryuz S, Ankerst DP, Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008;65(3):255-63
   PubMed Web of Science ®Google Scholar
• Goldstein JA. Danazol and the rapid-cycling patient. J Clin Psychiatry 1986;47(3):153-4
   PubMed Web of Science ®Google Scholar
• Mallinger AG, Thase ME, Haskett R, Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disord 2008;10(8):856-66
   PubMed Web of Science ®Google Scholar
• Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 2012;73(1):81-6
   PubMed Web of Science ®Google Scholar
• Maes M, Delange J, Ranjan R, Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997;66(1):1-11
   PubMed Web of Science ®Google Scholar
• Shaltiel G, Chen G, Manji HK. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 2007;7(1):22-6
   PubMed Web of Science ®Google Scholar
• Moorhead TW, McKirdy J, Sussmann JE, Progressive gray matter loss in patients with bipolar disorder. Biol Psychiatry 2007;62(8):894-900
   PubMed Web of Science ®Google Scholar
• Cunha AB, Frey BN, Andreazza AC, Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006;398(3):215-19
   PubMed Web of Science ®Google Scholar
• Gonul AS, Akdeniz F, Taneli F, Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005;255(6):381-6
   PubMed Web of Science ®Google Scholar
• Tramontina JF, Andreazza AC, Kauer-Sant'anna M, Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett 2009;452(2):111-13
   PubMed Web of Science ®Google Scholar
• Fukumoto T, Morinobu S, Okamoto Y, Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001;158(1):100-6
   PubMed Web of Science ®Google Scholar
• Frey BN, Andreazza AC, Cereser KM, Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 2006;79(3):281-6
   PubMed Web of Science ®Google Scholar
• Fernandes BS, Gama CS, Cereser KM, Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011;45(8):995-1004
   PubMed Web of Science ®Google Scholar
• Seifuddin F, Mahon PB, Judy J, Meta-analysis of genetic association studies on bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2012;159B(5):508-18
   PubMed Web of Science ®Google Scholar
• Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011;43(10):977-83
   PubMed Web of Science ®Google Scholar
• D'Addario C, Dell'Osso B, Palazzo MC, Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacology 2012;37(7):1647-55
   PubMed Web of Science ®Google Scholar
• Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007;8(5):355-67
   PubMed Web of Science ®Google Scholar
• Tsankova NM, Berton O, Renthal W, Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006;9(4):519-25
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Ibrahim L, Zarate CA Jr. Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci Ther 2011;17(6):699-704
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Zhang F, Huang EY, Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276(39):36734-41
   PubMed Web of Science ®Google Scholar
• Sharma RP, Rosen C, Kartan S, Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population. Schizophr Res 2006;88(1-3):227-31
   PubMed Web of Science ®Google Scholar
• Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403(6765):41-5
   PubMed Web of Science ®Google Scholar
• Chalmers S, Nicholls DG. The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria. J Biol Chem 2003;278(21):19062-70
   PubMed Web of Science ®Google Scholar
• Liu H, Bowes RC III, van de Water B, Endoplasmic reticulum chaperones GRP78 and calreticulin prevent oxidative stress, Ca2+ disturbances, and cell death in renal epithelial cells. J Biol Chem 1997;272(35):21751-9
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ, A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856-64
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67(8):793-802
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Brutsche NE, Ibrahim L, Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71(11):939-46
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu RJ, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329(5994):959-64
   PubMed Web of Science ®Google Scholar
• Koukopoulos A, Reginaldi D, Serra G, Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disord 2010;12(3):348-9
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Hsu HA, Papadakis K, Russo J Jr. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol 2009;32(4):199-204
   PubMed Web of Science ®Google Scholar
• Du J, Suzuki K, Wei Y, The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007;32(4):793-802
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Payne JL, Quiroz J, An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004;161(1):171-4
   PubMed Web of Science ®Google Scholar
• Sanacora G, Kendell SF, Levin Y, Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007;61(6):822-5
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Quiroz JA, Singh JB, An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005;57(4):430-2
   PubMed Web of Science ®Google Scholar
• Lourenco Da Silva A, Hoffmann A, Dietrich MO, Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology 2003;48(1):27-30
   PubMed Web of Science ®Google Scholar
• Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl) 2005;179(1):154-63
   PubMed Web of Science ®Google Scholar
• Charney DS, Manji HK. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE 2004;2004(225):re5
   PubMedGoogle Scholar
• Burdick KE, Braga RJ, Nnadi CU, Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry 2012;73(1):103-12
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Payne JL, Singh J, Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56(1):54-60
   PubMed Web of Science ®Google Scholar
• Berk M, Dean OM, Cotton SM, Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med 2012;10:91
   PubMed Web of Science ®Google Scholar
• Nicoletti VG, Marino VM, Cuppari C, Effect of antioxidant diets on mitochondrial gene expression in rat brain during aging. Neurochem Res 2005;30(6-7):737-52
   PubMed Web of Science ®Google Scholar
• Gawryluk JW, Wang JF, Andreazza AC, Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011;14(1):123-30
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov DL, Dean O, N-acetyl cysteine for depressive symptoms in bipolar disorder–a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64(6):468-75
   PubMed Web of Science ®Google Scholar
• Winsberg ME, Sachs N, Tate DL, Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry 2000;47(6):475-81
   PubMed Web of Science ®Google Scholar
• Forester BP, Zuo CS, Ravichandran C, Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. J Geriatr Psychiatry Neurol 2012;25(1):43-50
   PubMed Web of Science ®Google Scholar
• Post RM. Promising avenues of therapeutics for bipolar illness. Dialogues Clin Neurosci 2008;10(2):193-201
   PubMedGoogle Scholar
• Maes M, Goossens F, Scharpe S, Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res 1995;58(3):217-25
   PubMed Web of Science ®Google Scholar
• Bahtiyar G, Weiss K, Sacerdote AS. Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. Endocr Pract 2007;13(6):601-8
   PubMedGoogle Scholar
• Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008;5(3):481-9
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Woldeyohannes HO, A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord 2012;14(7):697-706
   PubMed Web of Science ®Google Scholar
• Brietzke E, Kapczinski F, Grassi-Oliveira R, Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother 2011;11(7):1017-28
   PubMed Web of Science ®Google Scholar
• Fields RD, Burnstock G. Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci 2006;7(6):423-36
   PubMed Web of Science ®Google Scholar
• Salvadore G, Viale CI, Luckenbaugh DA, Increased uric acid levels in drug-naive subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(6):819-21
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Soares JC, Lara DR, A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008;69(8):1237-45
   PubMed Web of Science ®Google Scholar
• Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs 2012;21(10):1503-22
   PubMed Web of Science ®Google Scholar
• Nurnberger JI Jr, Berrettini W, Tamarkin L, Supersensitivity to melatonin suppression by light in young people at high risk for affective disorder. A preliminary report. Neuropsychopharmacology 1988;1(3):217-23
   PubMed Web of Science ®Google Scholar
• Norris ER, Karen B, Correll JR, A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J Affect Disord 2013;144(1-2):141-7
   PubMed Web of Science ®Google Scholar
• Hoertel N, Le Strat Y, Lavaud P, Generalizability of clinical trial results for bipolar disorder to community samples: findings from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2013;74(3):265-70
   PubMed Web of Science ®Google Scholar
• Hoertel N, Le Strat Y, Gorwood P, Why does the lifetime prevalence of major depressive disorder in the elderly appear to be lower than in younger adults? Results from a national representative sample. J Affect Disord 2013; doi:pii: S0165-0327(13)00072-4. 10.1016/j.jad.2013.01.017
   Web of Science ®Google Scholar
• Hoertel N, Le Strat Y, Blanco C, Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depress Anxiety 2012;29(7):614-20
   PubMed Web of Science ®Google Scholar
• Hoertel N, Le Strat Y, De Maricourt P, Are subjects in treatment trials of panic disorder representative of patients in routine clinical practice? Results from a national sample. J Affect Disord 2013;146(3):383-9
   PubMed Web of Science ®Google Scholar
• Bouaziz M, Ambroise C, Guedj M. Accounting for population stratification in practice: a comparison of the main strategies dedicated to genome-wide association studies. PLoS One 2011;6(12):e28845
   PubMed Web of Science ®Google Scholar
• Tordjman S, Drapier D, Bonnot O, Animal models relevant to schizophrenia and autism: validity and limitations. Behav Genet 2007;37(1):61-78
   PubMed Web of Science ®Google Scholar
• Bandura DR, Baranov VI, Ornatsky OI, Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem 2009;81(16):6813-22
   PubMed Web of Science ®Google Scholar
• Schwarz E, Izmailov R, Spain M, Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 2010;5:39-47
   PubMedGoogle Scholar
• Brennand KJ, Simone A, Jou J, Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011;473(7346):221-5
   PubMed Web of Science ®Google Scholar
• Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116(Pt 7):1175-86
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007;9(6):628-35
   PubMed Web of Science ®Google Scholar
• Fornaro M, McCarthy MJ, De Berardis D, Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatr Dis Treat 2013;9:243-51
   PubMed Web of Science ®Google Scholar